Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials

$3,495.00

Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
December 2020
Number of pages
350+
Product type
Therapy profile
Available formats
PDF document
Report edition
2
SKU
CP2218

Global Genetic Disorders Partnering 2014 to 2020 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

 

  • Trends in Genetic Disorders partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genetic Disorders partnering agreement structure
  • Genetic Disorders partnering contract documents
  • Top Genetic Disorders deals by value
  • Most active Genetic Disorders dealmakers

 

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

 

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

 

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

 

Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

 

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

 

Chapter 4 provides a review of the leading Genetic Disorders deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2014. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2014.  

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

 

Report scope

 

Global Genetic Disorders Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

 

Global Genetic Disorders Partnering 2014 to 2020 includes:

 

  • Trends in Genetic Disorders dealmaking in the biopharma industry since 2014
  • Analysis of Genetic Disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genetic Disorders deal contract documents
  • Comprehensive access to over 500 Genetic Disorders deal records
  • The leading Genetic Disorders deals by value since 2014
  • Most active Genetic Disorders dealmakers since 2014

 

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

 

In Global Genetic Disorders Partnering 2014 to 2020, available deals and contracts are listed by:

 

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Genetic Disorders Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 500 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Genetic Disorders Partnering 2014 to 2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Genetic Disorders deal trends since 2014
  • Access Genetic Disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genetic Disorders partner companies
  • Comprehensive access to over 500 links to actual Genetic Disorders deals entered into by the world’s biopharma companies
  • Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genetic Disorders opportunities
  • Uncover companies actively partnering Genetic Disorders opportunities

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Genetic Disorders dealmaking

 

2.1. Introduction

2.2. Genetic Disorders partnering over the years

2.3. Genetic Disorders partnering by deal type

2.4. Genetic Disorders partnering by industry sector

2.5. Genetic Disorders partnering by stage of development

2.6. Genetic Disorders partnering by technology type

2.7. Genetic Disorders partnering by therapeutic indication

 

Chapter 3 –Financial deal terms for Genetic Disorders partnering

 

3.1. Introduction

3.2. Disclosed financials terms for Genetic Disorders partnering

3.3. Genetic Disorders partnering headline values

3.4. Genetic Disorders deal upfront payments

3.5. Genetic Disorders deal milestone payments

3.6. Genetic Disorders royalty rates

 

Chapter 4 – Leading Genetic Disorders deals and dealmakers

 

4.1. Introduction

4.2. Most active in Genetic Disorders partnering

4.3. List of most active dealmakers in Genetic Disorders

4.4. Top Genetic Disorders deals by value

 

Chapter 5 – Genetic Disorders contract document directory

                                            

5.1. Introduction

5.2. Genetic Disorders partnering deals where contract document available

 

Chapter 6 – Genetic Disorders dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by Genetic Disorders therapeutic target

 

Appendices

 

Appendix 1 – Directory of Genetic Disorders deals by company A-Z since 2014

Appendix 2 – Directory of Genetic Disorders deals by deal type since 2014

Appendix 3 – Directory of Genetic Disorders deals by stage of development since 2014

Appendix 4 – Directory of Genetic Disorders deals by technology type since 2014

Further reading on dealmaking

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Genetic Disorders partnering since 2014

Figure 2: Genetic Disorders partnering by deal type since 2014

Figure 3: Genetic Disorders partnering by industry sector since 2014

Figure 4: Genetic Disorders partnering by stage of development since 2014

Figure 5: Genetic Disorders partnering by technology type since 2014

Figure 6: Genetic Disorders partnering by indication since 2014

Figure 7: Genetic Disorders deals with a headline value

Figure 8: Genetic Disorders deals with upfront payment values

Figure 9: Genetic Disorders deals with milestone payment

Figure 10: Genetic Disorders deals with royalty rates

Figure 11: Active Genetic Disorders dealmaking activity since 2014

Figure 12: Top Genetic Disorders deals by value since 2014

   

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2bPrecise, 3DR Labs, 4D Molecular Therapeutics, 23andMe, AAVLife, Abbvie, Abby Grace Foundation, Abeona Therapeutics, Acucela, AdAlta, Addex Therapeutics, ADMA Biologics, Aequus Pharmaceuticals, Aevi Genomic Medicine, Affectis Pharmaceuticals, Affinia Therapeutics, Affymetrix, Agena Bioscience, AgeX Therapeutics, Agilis Biotherapeutics, AGTC, AiCuris, AiLife Diagnostics, Akcea Therapeutics, Akouos, Alana Healthcare, Albany Molecular Research, Alcyone Lifesciences, Aldevron, Aldeyra Therapeutics, Alexion Pharmaceuticals, AllCells, Allergan, Alnylam Pharmaceuticals, Altamira Bio, Altamira Pharma, Altius Institute for Biomedical Sciences, Ambry Genetics, American Heart/Stroke Association, American Society of Hematology, American Society of Human Genetics, AmerisourceBergen, Amgen, Amgros, Amicus Therapeutics, AMO Pharma, AmorChem, Amryt, AnchorDx, Angelini Pharma, Angion Biomedica, Annapurna Therapeutics, Antabio, Anthera Pharmaceuticals, ANZAC Reserach Institute, AOP Orphan Pharmaceuticals, APG Bio, Arbor Biotechnologies, Arch Biopartners, ARCHIMEDlife, Arcturus Therapeutics, Arecor, Aridis Pharmaceuticals, Ariosa Diagnostics, ArmaGen, ArQule, Aruvant Sciences, Asklepion Pharmaceuticals, Asklepios Biopharmaceutical, Astellas Pharma, AstraZeneca, Asuragen, Atomwise, Attain Health, Auburn University, Audentes Therapeutics, Avrobio, Axovant Gene Therapies, Azzur Group, Bambino Gesu Children’s Hospital, Bayer, Baylor College of Medicine, Baylor Genetics, Beam Therapeutics, Berg, Beyond Batten Disease Foundation, BGI Americas, Bicycle Therapeutics, Bill and Melinda Gates Foundation, BillionToOne, biOasis Technologies, BioAxone Therapeutic, BioBlast Pharma, Biogen, Biohealth Innovation, Bioiatriki, BioMarin Pharmaceutical, Biomedical Catalyst Fund (UK), Biomnis, Biopharma-Middle East and Africa, BioPontis Alliance, BioRealm, BioSensics, Bioverativ, BioXcel, Blackstone Medical, Bloom Burton, Bluebird Bio, Blueprint Genetics, Blueprint Medicines, Boehringer Ingelheim, Brammer Bio, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Buck Institute for Age Research, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calimmune, Calithera Biosciences, Camurus, CANbridge Life Sciences, Cancer Prevention and Research Institute of Texas, Cancer Prevention Pharmaceuticals, Capnia, CARB-X, Cardiff University, Cardinal Health, Carmine Therapeutics, Case Western Reserve University, Casma Therapeutics, Castle Creek Pharmaceuticals, Catalent, Celgene, Center for Human Genetics and Laboratory Medicine, Center for Inherited Blood Disorders, Centers for Disease Control and Prevention, Centogene, Centre for Drug Research and Development (CDRD), Certara, CFTechnology.org, Charcot-Marie-Tooth Association, Charles River Laboratories, CHDI Foundation, ChemDiv, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's Mercy Hospital, Children's National Health System, Children’s Hospital Oakland Research Institute (CHORI), Chondrial Therapeutics, ChromaDex, Cincinnati Children’s Hospital Medical Center, Claire's Place Foundation, Claritas Genomics, Clementia Pharmaceuticals, Clinic for Special Children, Clinigen, Clinuvel Pharmaceuticals, Columbia University, Columbia University Medical Center, Concert Pharmaceuticals, Confluence Pharmaceuticals, Congenica, ContraFect, Corbus Pharmaceuticals, Courtagen Life Sciences, CRISPR Therapeutics, CTD Holdings, Cure Duchenne, Cure Sanfilippo Foundation, CURx Pharmaceuticals, Cyclacel Pharmaceuticals, Cyclica, Cypher Genomics, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cystic Fibrosis Trust, Cystinosis Research Foundation, Dainippon Sumitomo Pharma, Daktari Diagnostics, Dalton Pharma Services, DarioHealth, DaRui Biotech, David and Barbara Roux, DBV Technologies, de Duve Institute, DefiniGEN, Department of Health and Human Services, Department of Veterans Affairs, Dermelix Biotherapeutics, DiamiR, Dicerna Pharmaceuticals, Dilaforette, Dimension Therapeutics, DMS Health Technologies, Duchenne Therapy Network, Duke University, Dynacure, Dystrophic Epidermolysis Bullosa Research Association of America, Edico Genome, Edimer Pharmaceuticals, Editas Medicine, EffRx, Eidos Therapeutics, Eiger BioPharmaceuticals, Elevian, Elexopharm, Eli Lilly, Elixirgen, Elucigene, Eluthia, Emergent BioSolutions, Emmaus Life Sciences, Emmaus Medical, Emory University, Emtora Biosciences, EnBiotix, Enterprise Therapeutics, Enzyvant Science, EpiDestiny, Ergomed, Erytech, EspeRare Foundation, Essentialis, Esteve, Eureka Eurostars, Eureka Genomics, EUSA Pharma, Evotec, Evox Therapeutics, Ewopharma, Excelra, Exemplar Genetics, Exicure, ExScientia, Fabric Genomics, Facio Therapies, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fertility SOURCE Companies, Fibrocell Science, Flemish agency for Innovation by Science and Technology, Fluidigm, Fluxion Biosciences, Fondazione Telethon, Food and Drug Administration (FDA), Fortress Biotech, Forty Seven, Foundation For Angelman Syndrome Therapeutics, Foundation for the Children of the Californias, Foundation to Fight H-ABC, Fox Chase Cancer Center, FRAXA Research Foundation, Fred Hutchinson Cancer Research Center, Friedreichs Ataxia Research Alliance, FSHD Global Research Foundation, Fudan University, Fujitsu Laboratories, Fulcrum Therapeutics, Fulgent Genetics, GACI Global, Gain Therapeutics, Galapagos, Gamida Cell, Geisinger Health System, Gen, Genable Technologies, Genea Biocells, GeneDX, Genentech, GenePeeks, Genethon, Genetic Alliance, GeneTx Biotherapeutics, Geneva University Hospitals, Genoma, Genome Institute of Singapore, Genomic Vision, Genosity, Genzyme, George Washington University, Gilead Sciences, GlaxoSmithKline, Global Blood Therapeutics, Global Genes, GNS Healthcare, Good Start Genetics, Grace Wilsey Foundation, Great Ormond Street Hospital (GOSH), Greenlight Biosciences, GtreeBNT, Harvard University, Helix, Hereditary Neuropathy Foundation, Hillhurst Biopharmaceuticals, Horizon Discovery, Horizon Pharma plc, Icagen, Icahn School of Medicine at Mount Sinai, Igentify, Illumina, Immuneering, ImmunoQure, Imperial College London, Imperial Innovations, In-Depth Genomics, Inceptua, Indiana University, Indiana University-Purdue University Indianapolis, Indian Institute of Science Education and Research, InformedDNA, Inhibrx, Innovate UK, Inova Translational Medicine Institute, Inozyme Pharma, Inserm, Inserm Transfert, Insight Centre for Data Analytics, Insilico, In Silico Biosciences, Insmed Inc, InSphero, Institute for Genome Statistics and Bioinformatics, Institute of Child Health, Institute of Human Genetics, Institut Pasteur, Intel, Intellia Therapeutics, Intrexon, Intrinsic LifeSciences, Invitae, Ionis Pharmaceuticals, Ipsen, ISIS Innovation, Israeli Ministry of Industry and Commerce, Italfarmaco, Iveric Bio, IXICO, Jackson Laboratory, James R Clark Memorial Sickle Cell Foundation, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Jeffrey Modell Foundation, Johns Hopkins University, Jupiter Orphan Therapeutics, Juvenescence, K-PAX Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, Keio Gijuku University, Kings College London, Komodo Health, Laboratory Corporation of America, La Jolla Pharmaceutical, Lannett, La Paz Hospital, Laurel Therapeutics, Laurent Pharmaceuticals, Lead Discovery Center, Leadiant Biosciences, Leidos, Lenus Therapeutics, Les Laboratoires Servier, Levo Therapeutics, LFB Biotechnologies, Ligand Pharmaceuticals, Linda Crnic Institute for Down Syndrome, LineaRx, LogicBio Therapeutics, Louisiana State University, Lovelace Biomedical and Environmental Research Institute, Lumicera Health Services, Luminex, Lundbeck, Lysando, Lysogene, Magenta Therapeutics, Mallinckrodt Pharmaceuticals, ManRos Therapeutics, Marnier-Lapostolle Foundation, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, Matinas Biopharma, Mauli Ola Foundation, Maxcyte, Maxor National Pharmacy, MC10, McGill University, McKesson, Medgenics, Medical College of Wisconsin, Medical University of South Carolina, Medison Pharma, MedPharm, MeiraGTx, Merck and Co, Merck KGaA, Microbion, Microsoft, Minoryx Therapeutics, Mitsubishi Tanabe Pharma, Modalis Therapeutics, Moderna Therapeutics, Molecular Stethoscope, Molecular Templates, Morphic Therapeutic, Mount Sinai Medical Center, Murdoch Childrens Research Institute, Muscular Dystrophy Association, Mustang Bio, Mylan Laboratories, Myriad Genetics, Nanopharmacia, NantHealth, Napa Therapeutics, Natera, National Center for Advancing Translational Sciences (NCATS), National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, National Newspaper Publishers Association, National Organization for Rare Disorders, National Psoriasis Foundation, National Science Foundation, National Taiwan University Hospital, Nationwide Children’s Hospital, Navitas, Necker Hospital, Neurocrine Biosciences, NeuroCycle Therapeutics, NeuroPointDX, Neurotrope BioScience, NeuroVive Pharmaceutical, Newron Pharmaceuticals, New York Blood Center, New Zealand Pharmaceuticals, NextCODE Health, NextGxDx, NightstaRx, Nippon Chemiphar, Nippon Shinyaku, NMI TT Pharmaservices, Novartis, NovaSignal, Novation, Novogen, Novo Nordisk, Novoteris, Numedicus, NuvoAir, Oncology Supply, Onconova Therapeutics, OptraHEALTH, Oraxion Therapeutics, Orchard Therapeutics, ORIG3N, Origin Biosciences, Orsini Healthcare Specialty Pharmacy, Oryzon, OSI Pharmaceuticals, Ovid Therapeutics, Oxford BioMedica, Pacific Biosciences, Palvella Therapeutics, ParcelShield, Parion Sciences, PARI Pharma, Paris Descartes University, Parkinson's Institute and Clinical Center, Passage Bio, Path BioAnalytics, Patheon, Pathway Genomics, PatientsLikeMe, PCT, PerkinElmer, Perlara, Perrigo, Personalis, Pfizer, PharmaCell, Pharmaxis, Pharming Group, Pharnext, Phase Genomics, PicnicHealth, PierianDx, PlasmaTech Biopharmaceuticals, Plasticell, PoC Capital, Polyphor, Portable Genomics, Prader-Willi Research, Prevencio, PreventionGenetics, Prime Medicine, Progenitor Cell Therapy, Progeria Research Foundation, ProPath, Prophylix Pharma, ProQR Therapeutics, Proteostasis Therapeutics, Prothelia, PSC Biotech, PTC Therapeutics, Public Health England, PWNHealth, Q-State Biosciences, Qiagen, QoL Medical, QR Pharma, Queen Mary University of London, Questcor Pharmaceuticals, Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Rallybio, RaNA Therapeutics, Raptor Pharmaceutical, Rare Diseases Clinical Research Network, Rare Genomics Institute, Recombinetics, Recordati, Recursion, Regenacy Pharmaceuticals, Regeneron Genetics Center, Regeneron Pharmaceuticals, Regenxbio, ReGenX Biosciences, Repligen, Reproductive Medicine Associates of New York, Resonance Health, RespirTech, Retrophin, RetroSense Therapeutics, Retrotope, Rett Syndrome Research Trust, rEVO Biologics, Rhythm Pharmaceuticals, Roche, Roche Diagnostics, Rockefeller University, Rocket Pharmaceuticals, Rockland Immunochemicals, Roivant Sciences, Rosalind Franklin University of Medical Sciences, RUCDR Infinite Biologics, Salk Institute, Salud Interactiva, Sangamo BioSciences, Sanofi, Sanofi-Genzyme BioVentures, Santhera Pharmaceuticals, Saphetor, Sarepta Therapeutics, Scarab Genomics, Scholar Rock, Scripps Research Institute, Seattle Children's Hospital, Seattle Childrens Research Institute, Seelos Therapeutics, Selecta Biosciences, Sema4, Semmelweis University, Sensorion, Sentieon, Sentinel Oncology, Sequenom, Seres Therapeutics, Sharp Edge Labs, Shionogi Pharma, Shire Laboratories, Shire Pharmaceuticals, Sickle Cell Disease Foundation, Sickle Cell Foundation of Georgia, Singulex, Sirona Biochem, Skyhawk Therapeutics, SkylineDX, SOM Biotech, Sosei Heptares, Sound Pharmaceuticals, Spark Therapeutics, Sperogenix Therapeutics, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Stealth Therapeutics, StemCyte, StemoniX, Stony Brook University, StrideBio, Strongbridge Biopharma, Sturge-Weber Foundation, Sucampo AG, Sucampo Pharmaceuticals, Sutter Health, Suzhou NeuPharma, Swedish Orphan Biovitrum, Swixx Biopharma, Synspira, Synteract, Syros Pharmaceuticals, T-TOP Clinical Research, Taiba, Takeda America Holdings, Takeda Pharmaceutical, Talee Bio, TARGET PharmaSolutions, Taro Pharmaceuticals, Tasly Pharmaceuticals, Taysha Gene Therapies, Team Sanfilippo, Tekmira Pharmaceuticals, Tel Aviv University, Tetra Discovery Partners, Teva Pharmaceutical Industries, Texas Children’s Hospital, The BioCollective, The HUB Foundation, The Human Protein Atlas, The MAVEN Project (Medical Alumni Volunteer Expert Network), The Nemours/Alfred I duPont Hospital for Children, Theraly Fibrosis, Tillotts Pharma, Traffick Therapeutics, Transgenomic, Transition Therapeutics, Translate Bio, Translational Medicine Accelerator, Tripex Pharmaceuticals, Tuberous Sclerosis Alliance (TS Alliance), Turing Pharmaceuticals, Twist Bioscience, UK Cystic Fibrosis Gene Therapy Consortium, Ultragenyx Pharmaceuticals, UNeMed, UniQure, UnitedHealthcare, Universite catholique de Louvain, Universite Laval, University College Dublin, University College London, University of Alabama, University of Auckland, University of Bonn, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Connecticut, University of Edinburgh, University of Florida, University of Kentucky, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Nebraska, University of Nevada, University of North Carolina, University of Notre of Dame, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Quebec, University of Rochester, University of South Florida, University of Texas Southwestern Medical Center, University of Toledo, University of Utah, University of Vermont, University of Virginia, University of Washington, University of Zambia, University of Zurich, US Bioservices, Vaccinex, Valeant Pharmaceuticals, Valeo Pharma, Vanda Pharmaceuticals, Vanderbilt University, Vertex Pharmaceuticals, Victorian Clinical Genetics Services, Viking Therapeutics, Vinnova, Viralgen, Visikol, Vivet Therapeutics, Voyager Therapeutics, Wake Forest University, Warren Family Research Center for Drug Discovery and Development, Washington University in St Louis, WAVE Life Sciences, Weill Cornell Medical College, Wellcome Trust, Winhealth Pharma Group, Wired Holdings, WuXi Biologics, WuXi NextCODE Genomics, X4 Pharmaceuticals, XL-Protein, Yale University, Yungjin Pharmaceutical, YuYang DNU, Zedira, Zoetis, Zogenix

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.